Schering Corporation

Pharmacopeia Drug Discovery, Inc.

Doublas W Hobbs

Neng-Yang Shih

Joseph A Kozlowski

Stuart B Rosenblum

Wensheng Yu

Brian F McGuinness

Michael K C Wong

Seong Heon Kim

De-Yi Yang

Qingbei Zeng

Gopinadhan N Anilkumar

Lisa Guise Zawacki

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates or esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity

Growing community of inventors

Yardley, PA, United States of America

Doublas W Hobbs